2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

peptide drug conjugate

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

1

Fluorescent Dye

10

Biochemical Assay Reagents

25

Peptides

1

Inhibitory Antibodies

1

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19813A
    mDPR-Val-Cit-PAB-MMAE TFA

    		Drug-Linker Conjugates for ADC Cancer
    mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition [1] .
    mDPR-Val-Cit-PAB-MMAE TFA
  • HY-106244A
    DOTATATE acetate
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-106244
    DOTATATE
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-P10895
    HR97 TFA

    		Biochemical Assay Reagents Others
    HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .
    HR97 TFA
  • HY-147021
    MC-Val-D-Cit-PAB-PNP

    		ADC Linker Cancer
    MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.
    MC-Val-D-Cit-PAB-PNP
  • HY-P10741
    DOTA-EB-TATE

    		Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor Cancer
    DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-EB-TATE
  • HY-129360
    Ala-Ala-Asn-PAB

    		ADC Linker Cancer
    Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
    Ala-Ala-Asn-PAB
  • HY-129360A
    Ala-Ala-Asn-PAB TFA

    		ADC Linker Cancer
    Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
    Ala-Ala-Asn-PAB TFA
  • HY-128937
    EC1454

    		Liposome Folate Receptor (FR) Cancer
    EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
    EC1454
  • HY-164166
    Fmoc-Sar-Sar-Sar-OH

    		Biochemical Assay Reagents Others
    Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .
    Fmoc-Sar-Sar-Sar-OH
  • HY-150241
    DOPE-NHS

    		Liposome Others
    DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .
    DOPE-NHS
  • HY-P2218
    Anditixafortide

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Anditixafortide
  • HY-153395
    PH-HG-005-5

    		Drug-Linker Conjugates for ADC Cancer
    PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .
    PH-HG-005-5
  • HY-P10742
    CBX-12

    		Peptide-Drug Conjugates (PDCs) Topoisomerase Cancer
    CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .
    CBX-12
  • HY-13631E
    Deruxtecan
    Maximum Cited Publications
    19 Publications Verification

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-P99881
    Rolinsatamab talirine

    ABBV 176

    		 Drug-Linker Conjugates for ADC Cancer
    Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
    Rolinsatamab talirine
  • HY-P10757
    DTX-P7

    		Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK Cancer
    DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .
    DTX-P7
  • HY-153549
    Pentixafor

    		Radionuclide-Drug Conjugates (RDCs) CXCR Others
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-158199
    BCN-HS-PEG2-bis(PNP)

    		ADC Linker Cancer
    BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
    BCN-HS-PEG2-bis(PNP)
  • HY-172270D
    DSPE-PEG5000-Mal-Cys-KTLLPTP

    		Liposome Cancer
    DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
    DSPE-PEG5000-Mal-Cys-KTLLPTP
  • HY-172270C
    DSPE-PEG3400-Mal-Cys-KTLLPTP

    		Liposome Cancer
    DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
    DSPE-PEG3400-Mal-Cys-KTLLPTP
  • HY-172270
    DSPE-PEG1000-Mal-Cys-KTLLPTP

    		Liposome Cancer
    DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
    DSPE-PEG1000-Mal-Cys-KTLLPTP
  • HY-172270A
    DSPE-PEG2000-Mal-Cys-KTLLPTP

    		Liposome Cancer
    DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
    DSPE-PEG2000-Mal-Cys-KTLLPTP
  • HY-138298
    Trastuzumab deruxtecan (solution)
    1 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-138298A
    Trastuzumab deruxtecan
    1 Publications Verification

    DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-W071967
    Alloc-Val-Ala-pAB

    		ADC Linker Cancer
    Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
    Alloc-Val-Ala-pAB
  • HY-172273B
    DSPE-PEG5000-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG5000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG5000-M2pep can be used for drug delivery .
    DSPE-PEG5000-Mal-Cys-YEQDPWGVKWWY
  • HY-172273A
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG2000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-M2pep can be used for drug delivery .
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY
  • HY-172273
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY
  • HY-172273C
    DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG3400-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG3400-M2pep can be used for drug delivery .
    DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY
  • HY-13631ES4
    Deruxtecan-d5

    MC-GGFG-DXD-d5

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d5
  • HY-13631ES
    Deruxtecan-d4

    MC-GGFG-DXD-d4

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4
  • HY-13631ES3
    Deruxtecan-d2

    MC-GGFG-DXD-d2

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d2
  • HY-13631ES2
    Deruxtecan-d4-1

    MC-GGFG-DXD-d4-1

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4-1
  • HY-125586
    β-Amanitin

    		DNA/RNA Synthesis ADC Payload Cancer
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    β-Amanitin
  • HY-W729138
    Fmoc-D-homoArg(Et)2-OH hydrochloride

    		ADC Linker Others
    Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .
    Fmoc-D-homoArg(Et)2-OH hydrochloride
  • HY-P10307
    DOTA-ubiquicidin (29–41)

    		Radionuclide-Drug Conjugates (RDCs) Bacterial Infection
    DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-ubiquicidin (29–41)
  • HY-P5297
    DOTA-CXCR4-L

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-CXCR4-L
  • HY-P10740
    CBP-1018

    		Peptide-Drug Conjugates (PDCs) Antifolate Cancer
    CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
    CBP-1018
  • HY-P10770
    P-ESBP-DOX

    		Peptide-Drug Conjugates (PDCs) E-Selectin Cardiovascular Disease Cancer
    P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
    P-ESBP-DOX
  • HY-P10762
    Ricorfotide vedotin

    CBP-1008; LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    Ricorfotide vedotin
  • HY-P10760
    PhAc-ALGP-Dox

    		Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Payload Cancer
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
    Auristatin E
  • HY-P4073
    ANG1005

    GRN1005; Paclitaxel trevatide

    		 Peptide-Drug Conjugates (PDCs) LDLR Cancer
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
    ANG1005
  • HY-13631EG
    Deruxtecan

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-164992
    Trastuzumab vedotin

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer .
    Trastuzumab vedotin
  • HY-P10947
    MACTIDE-V

    		Epigenetic Reader Domain YAP Cancer
    MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
    MACTIDE-V
  • HY-P10761
    DPI-4452

    		Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase Cancer
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DPI-4452
  • HY-115693
    CAP 3

    		Bacterial Infection
    CAP 3 is a cholic acid-peptide conjugate (CAP) antimicrobial agent. CAP 3 effectively inhibits Gram-negative bacteria, with MIC99 (minimum inhibitory concentration for 99% bacterial killing) values of 8 μM, 16 μM, and 16 μM against E. coli, Klebsiella pneumoniae and Acinetobacter baumannii, respectively. CAP 3 exerts its antibacterial effects by disrupting the structural integrity of the bacterial lipopolysaccharide (LPS) outer membrane. CAP 3 rapidly kills bacteria, inhibits biofilm formation, and effectively combats drug-resistant strains and persistent bacterial infections .
    CAP 3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: